Home / Medical Devices / Cardiac Markers Market By Type (Cardiac Troponin I And T, CK-MB, Myoglobin, B Type Natriuretic Peptide (BNP) And NT-proBNP, hs-C-Reactive Protein (hs-CRP), Myeloperoxidase (MPD), Ischaemia Modified Albumin, Others), By Product (Instruments, Reagents And Kits), By Condition (Plaque Formation, Plaque Instability/ Rupture, Myocardial Necrosis And Ischemia, Heart Failure), By Testing Type (Laboratory Testing, Point-of-Care Testing) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Cardiac Markers Market By Type (Cardiac Troponin I And T, CK-MB, Myoglobin, B Type Natriuretic Peptide (BNP) And NT-proBNP, hs-C-Reactive Protein (hs-CRP), Myeloperoxidase (MPD), Ischaemia Modified Albumin, Others), By Product (Instruments, Reagents And Kits), By Condition (Plaque Formation, Plaque Instability/ Rupture, Myocardial Necrosis And Ischemia, Heart Failure), By Testing Type (Laboratory Testing, Point-of-Care Testing) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Nov 2018 | Report Code: 59447-11-18

Industry Outlook

Cardiac markers are the substances that are released into the blood stream during heart damage. These markers are detected with specialized immunoassays and are used for diagnosis, evaluation and monitoring of patients with suspected acute coronary syndrome. These markers are very useful when patients do not present ischemic chest pain and have non-diagnostic ECG. The common cardiac markers used for evaluation of acute coronary syndrome are troponin I & T, CK-MB and myoglobins. Other biomarkers studied in this report are less specific in nature, but are also used for further evaluation, in terms of damage to the system. Considering their usefulness, cardiac biomarkers are vital for diagnosis of acute coronary syndrome, acute myocardial infraction, and heart failure and renal diseases; prognosis and risk stratification of patients with coronary syndrome, and for patients that are undergoing pre- and post-reperfusion and interventions.

Globally increasing prevalence of cardiovascular diseases, rapidly changing lifestyle and dietary patterns, increasing pool of high-risk geriatric population, and persistent growth in the nature of point-of-care diagnostic solutions are the key factors driving the growth of the global cardiac markers market. Conversely, high cost and less specificity of certain tests may hold back the growth of this market. Intensive R&D initiatives and success of the use of cardiac biomarkers in detection of congenital coronary diseases are some of the aspects that will open future opportunities in this market.

Market Synopsis

Cardiac Markers Market

Troponin Tests to Remain the Largest Revenue Segment

Troponin T and I enzymes are normal proteins that are vital for contractile apparatus of cardiac myocyte. These enzymes are released in the blood circulation between three and four hours of myocardial infraction and are detectable after up to ten days. Such long life of troponin allows for late diagnosis of myocardial infraction but are not successful in diagnosis of re-infraction. Higher uptake of troponin T & I tests is because these are more sensitive than creatine kinase (CK) and myoglobin. Monoclonal antibody tests are also being developed for detection of specific troponin T and cardiac specific troponin I. cardiac troponin are also used for diagnosis of chest pain in patients with non-diagnostic ECG. These tests are also used for prognosis of a myocardial infraction and identification of patients with high risk of cardiac events.

Cardiac Markers Market

Reagents and Kits, and Point-of-Care Testing to Remain the Market Leaders

Based on products, the global cardiac markers market is classified into reagents and kits, and instruments (chemiluminescence, immunofluorescence, immunochromatography and ELISA). Between the two, the demand for reagents and kits is set to remain the highest during the forecast period. Low costs and greater purchase volume are the key factors considered for the dominance of this segment. However, with technological evolution, the demand for analyzer instruments will remain stable throughout the forecast period. The market growth of the instruments segment is set to remain the highest in emerging markets of Asia Pacific, Latin America and Middle East and Africa, where the rapid development of healthcare infrastructure is being witnessed.  At present point-of-care (POC) immunoassays for several cardiac markers for troponin I & T, myoglobin and CK-MB are available in the market that deliver good quantitative and qualitative results comparable to traditional laboratory-based assays. POC cardiac markers are vital in evaluation of emergency room patients complaining of chest pain. POC assays ombining CK-MB and myoglobin have better sensitivity and specificity in diagnosis of myocardial infraction and may also offer earliest identification of myocardial injury. Troponin T assays are the most utilized in POC settings along with Troponin I.

Cardiac Markers Market

Myocardial Necrosis and Ischemia to Contribute Highest Revenue

Consistent increase in sedentary lifestyle, overall stress levels, changes in dietary habits, smoking and alcohol use, and growing geriatric population are the key factors that have resulted in growing incidence of myocardial infraction. The two well-known biomarkers used for diagnosis of acute myocardial infraction/necrosis are CK-MB and cardiac troponin. Since 2000, cardiac troponin has successfully replaced CK-MB as the marker of choice for diagnosis of myocardial infraction. Quick identification of acute myocardial infraction is deemed to be mandatory for initiation of effective treatment and better prognosis. Troponin T is present in the bound form to the contractile myocardial cells, and presents dual release of the cytoplasmic component. Troponin I also is extremely specific to the cardiac muscle. Their absolute specificity makes troponin I & T the ideal markers for myocardial necrosis.

Cardiac Markers Market

Asia Pacific to Have Significant Market Opportunities in Store

Currently, North America leads the global cardiac markers market, globally. High incidence of cardiac emergencies, significantly large proportion of population leading sedentary lifestyle along with high risk dietary profile are the basic factors supporting the dominance of North America market. Additionally, the availability of both POC and laboratory-based cardiac marker tests is also widespread in the region, along with supportive high awareness in the general population. However, Asia Pacific is anticipated to progress at the fastest CAGR during the forecast period. Large population pool, along with greater adoption of high sugar and fat diets are contributing to increasing prevalence of chronic heart diseases. This as therefore led to growth in adoption of advanced diagnostic tools for management of such patient pool. Additionally, as the medical tourism market in the region is flourishing, the demand for advanced diagnostic solutions for cardiac diseases is also on the growth. This has resulted in increased penetration of global market giants to augment their market penetration activities in the Asia Pacific market.

Cardiac Markers Market

Cardiac Markers Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each considered segment for the period from 2016 to 2026, having 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.

Cardiac Markers Market

Report Scope by Segments

The cardiac markers market report provides quantitative assessment of the industry terms of current and forecasted market size, while also presenting the market dynamics. This market is segmented based on type, products, conditions, testing type, and geography.

By Type (2016–2026; US$ Mn)

  • Cardiac Troponin I and T
  • CK-MB
  • Myoglobin
  • B type natriuretic peptide (BNP) and NT-proBNP
  • hs-C-Reactive Protein (hs-CRP)
  • Myeloperoxidase (MPD)
  • Ischaemia Modified Albumin
  • Others

By Products (2016–2026; US$ Mn)

  • Instruments
  • Chemiluminescence
  • Immunofluorescence
  • Immunochromatography
  • ELISA
  • Reagents and Kits

By Condition (2016–2026; US$ Mn)

  • Plaque Formation
  • Plaque Instability/ Rupture
  • Myocardial Necrosis and Ischemia
  • Heart Failure

By Testing Type (2016–2026; US$ Mn)

  • Laboratory Testing
  • Point-of-Care Testing

Geography Segment (2016–2026; US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • Japan
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of Middle East and Africa

The qualitative analysis presented in this report gives insights on the determinant market dynamics of the cardiac markers industry. Such market dynamics are classified as market drivers, challenges and opportunities. The major market players involved in cardiac biomarkers industry are also assessed in terms of their business overview, product portfolio, financial status and key developments. The prominent market players profiled in this report are Abbott Laboratories, Inc., Roche Diagnostics Limited, Danaher Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, LSI Medience Corporation, Beckman Coulter, Inc. (Danaher Corporation),

bioMerieux SA, Ortho Clinical Diagnostics, Siemens Healthcare Diagnostics, Randox Laboratories Ltd., Tosoh Bioscience and Quest Diagnostics, Inc.

Key questions answered in this report

  • What is the estimated market size and CAGR of the global cardiac markers industry during the forecast period from 2018 to 2026?
  • What are the key market drivers and pain points prevalent in the cardiac markers market?
  • In which direction is the CK-MB segment progressing and will it be challenged by other testing markers?
  • Will the demand of novel analyzer instruments rise during the forecast period?
  • What status do segments such as heart failure and myocardial infraction have in the global cardiac markers market?
  • At what CAGR will the point-of-care segment progress during the period from 2018 to 2026?
  • How the global competition progressing among the key market players?
  • Is there a possibility of new market entrants, particularly in the emerging markets of Asia Pacific?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Cardiac Markers Market Portraiture
2.2. Global Cardiac Markers Market, by Type, 2017 (US$ Mn)
2.3. Global Cardiac Markers Market, by Product, 2017 (US$ Mn)
2.4. Global Cardiac Markers Market, by Condition, 2017 (US$ Mn)
2.5. Global Cardiac Markers Market, by Testing Type, 2017 (US$ Mn)
2.6. Global Cardiac Markers Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Cardiac Markers Market: Dynamics and Future Outlook
3.1. Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Cardiac Markers Market, by Key Players, 2017

Chapter 4. Global Cardiac Markers Market, by Type, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Cardiac troponin I and T
4.3. CK-MB
4.4. Myoglobin
4.5. B type natriuretic peptide (BNP) and NT-proBNP
4.6. hs-C-Reactive Protein (hs-CRP)
4.7. Myeloperoxidase (MPD)
4.8. Ischaemia Modified Albumin
4.9. Others

Chapter 5. Global Cardiac Markers Market, by Product, 2016 - 2026 (US$ Mn)
5.1. Overview
5.2. Instruments
5.2.1. Chemiluminescence
5.2.2. Immunofluorescence
5.2.3. Immunochromatography
5.2.4. ELISA
5.3. Reagents and Kits

Chapter 6. Global Cardiac Markers Market, by Condition, 2016 - 2026 (US$ Mn)
6.1. Overview
6.2. Plaque Formation
6.3. Plaque Instability/ Rupture
6.4. Myocardial Necrosis and Ischemia
6.5. Heart Failure

Chapter 7. Global Cardiac Markers Market, by Testing Type, 2016 - 2026 (US$ Mn)
7.1. Overview
7.2. Laboratory Testing
7.3. Point-of-Care Testing

Chapter 8. Global Cardiac Markers Market, by Geography, 2016 – 2026 (US$ Mn)
8.1. Overview
8.1.1. North America Cardiac Markers Market, 2016 - 2026 (US$ Mn)
8.1.2. North America Cardiac Markers Market, by Type, 2016 - 2026 (US$ Mn)
8.1.3. North America Cardiac Markers Market, by Product, 2016 - 2026 (US$ Mn)
8.1.4. North America Cardiac Markers Market, by Condition, 2016 - 2026 (US$ Mn)
8.1.5. North America Cardiac Markers Market, by Testing Type, 2016 - 2026 (US$ Mn)
8.1.6. North America Cardiac Markers Market, by Country, 2016 – 2026 (US$ Mn)
8.1.6.1. U.S.
8.1.6.2. Canada
8.2. Europe Cardiac Markers Market, 2016 – 2026 (US$ Mn)
8.2.1. Europe Cardiac Markers Market, by Type, 2016 - 2026 (US$ Mn)
8.2.2. Europe Cardiac Markers Market, by Product, 2016 - 2026 (US$ Mn)
8.2.3. Europe Cardiac Markers Market, by Condition, 2016 - 2026 (US$ Mn)
8.2.4. Europe Cardiac Markers Market, by Testing Type, 2016 - 2026 (US$ Mn)
8.2.5. Europe Cardiac Markers Market, by Country/Region, 2016 – 2026 (US$ Mn)
8.2.5.1. U.K.
8.2.5.2. Germany
8.2.5.3. Rest of Europe
8.3. Asia Pacific Cardiac Markers Market, 2016 – 2026 (US$ Mn)
8.3.1. Asia Pacific Cardiac Markers Market, by Type, 2016 - 2026 (US$ Mn)
8.3.2. Asia Pacific Cardiac Markers Market, by Product, 2016 - 2026 (US$ Mn)
8.3.3. Asia Pacific Cardiac Markers Market, by Condition, 2016 - 2026 (US$ Mn)
8.3.4. Asia Pacific Cardiac Markers Market, by Testing Type, 2016 - 2026 (US$ Mn)
8.3.5. Asia Pacific Cardiac Markers Market, by Country/Region, 2016 – 2026 (US$ Mn)
8.3.5.1. China
8.3.5.2. Japan
8.3.5.3. Rest of Asia Pacific
8.4. Latin America Cardiac Markers Market, 2016 – 2026 (US$ Mn)
8.4.1. Latin America Cardiac Markers Market, by Type, 2016 - 2026 (US$ Mn)
8.4.2. Latin America Cardiac Markers Market, by Condition, 2016 - 2026 (US$ Mn)
8.4.3. Latin America Cardiac Markers Market, by Product, 2016 - 2026 (US$ Mn)
8.4.4. Latin America Cardiac Markers Market, by Testing Type, 2016 - 2026 (US$ Mn)
8.4.5. Latin America Cardiac Markers Market, by Country/Region, 2016 – 2026 (US$ Mn)
8.4.5.1. Brazil
8.4.5.2. Mexico
8.4.5.3. Rest of Latin America
8.5. Middle East & Africa Cardiac Markers Market, 2016 – 2026 (US$ Mn)
8.5.1. Middle East & Africa Cardiac Markers Market, by Type, 2016 - 2026 (US$ Mn)
8.5.2. Middle East & Africa Cardiac Markers Market, by Product, 2016 - 2026 (US$ Mn)
8.5.3. Middle East & Africa Cardiac Markers Market, by Condition, 2016 - 2026 (US$ Mn)
8.5.4. Middle East & Africa Cardiac Markers Market, by Testing Type, 2016 - 2026 (US$ Mn)
8.5.5. Middle East & Africa Cardiac Markers Market, by Region, 2016 – 2026 (US$ Mn)
8.5.5.1. GCC
8.5.5.2. Rest of Middle East & Africa

Chapter 9. Company Profiles
9.1. Abbott Laboratories, Inc.
9.1.1. Business Description
9.1.2. Financial Information (Subject to Data Availability)
9.1.3. Product Portfolio
9.1.4. Key Developments
9.2. Roche Diagnostics Limited
9.3. Danaher Corporation
9.4. Bio-Rad Laboratories, Inc.
9.5. Becton, Dickinson and Company
9.6. LSI Medience Corporation
9.7. Beckman Coulter, Inc. (Danaher Corporation)
9.8. bioMerieux SA
9.9. Ortho Clinical Diagnostics
9.10. Siemens Healthcare Diagnostics
9.11. Randox Laboratories Ltd.
9.12. Tosoh Bioscience
9.13. Quest Diagnostics, Inc.

FIG 1. Cardiac Markers Market: Research Methodology
FIG 2. Cardiac Markers: Market Segmentation
FIG 3. Global Cardiac Markers Market, by Type, 2017 (US$ Mn)
FIG 4. Global Cardiac Markers Market, by Product, 2017 (US$ Mn)
FIG 5. Global Cardiac Markers Market, by Condition, 2017 (US$ Mn)
FIG 6. Global Cardiac Markers Market, by Testing Type, 2017 (US$ Mn)
FIG 7. Global Cardiac Markers Market, by Geography, 2017 (US$ Mn)
FIG 8. Attractive Investment Proposition, by Geography, 2017
FIG 9. Competitive Analysis: Global Cardiac Markers Market, by Key Players, 2017
FIG 10. Global Cardiac troponin I and T Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 11. Global CK-MB Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 12. Global Myoglobin Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 13. Global B type natriuretic peptide (BNP) and NT-proBNP Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 14. Global hs-C-Reactive Protein (hs-CRP) Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 15. Global Myeloperoxidase (MPD) Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 16. Global Ischaemia Modified Albumin Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 17. Global Other Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 18. Global Chemiluminescence Cardiac Marker Instruments Market, 2016 - 2026 (US$ Mn)
FIG 19. Global Immunofluorescence Cardiac Marker Instruments Market, 2016 - 2026 (US$ Mn)
FIG 20. Global Immunochromatography Cardiac Marker Instruments Market, 2016 - 2026 (US$ Mn)
FIG 21. Global ELISA Cardiac Marker Instruments Market, 2016 - 2026 (US$ Mn)
FIG 22. Global Cardiac Marker Reagents and Kits Market, 2016 - 2026 (US$ Mn)
FIG 23. Global Cardiac Markers Market for Plaque Formation, 2016 - 2026 (US$ Mn)
FIG 24. Global Cardiac Markers Market for Plaque Instability/ Rupture, 2016 - 2026 (US$ Mn)
FIG 25. Global Cardiac Markers Market for Myocardial Necrosis and Ischemia, 2016 - 2026 (US$ Mn)
FIG 26. Global Cardiac Markers Market for Heart Failure, 2016 - 2026 (US$ Mn)
FIG 27. Global Cardiac Markers Market in Laboratory Testing, 2016 - 2026 (US$ Mn)
FIG 28. Global Cardiac Markers Market in Point-of-Care Testing, 2016 - 2026 (US$ Mn)
FIG 29. U.S. Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 30. Canada Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 31. U.K. Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 32. Germany Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 33. Rest of Europe Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 34. China Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 35. Japan Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 36. India Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 37. Rest of Asia Pacific Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 38. Brazil Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 39. Mexico Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 40. Rest of Latin America Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 41. GCC Cardiac Markers Market, 2016 - 2026 (US$ Mn)
FIG 42. Rest of Middle East and Africa Cardiac Markers Market, 2016 - 2026 (US$ Mn)

TABLE 1 Global Cardiac Markers Market Portraiture
TABLE 2 Global Cardiac Markers Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Cardiac Markers Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 4 Global Cardiac Marker Instruments Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 5 Global Cardiac Markers Market, by Condition, 2016 – 2026 (US$ Mn)
TABLE 6 Global Cardiac Markers Market, by Testing Type, 2016 – 2026 (US$ Mn)
TABLE 7 Global Cardiac Markers Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America Cardiac Markers Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 9 North America Cardiac Markers Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 10 North America Cardiac Markers Market, by Condition, 2016 – 2026 (US$ Mn)
TABLE 11 North America Cardiac Markers Market, by Testing Type, 2016 – 2026 (US$ Mn)
TABLE 12 North America Cardiac Markers Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 13 Europe Cardiac Markers Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 14 Europe Cardiac Markers Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 15 Europe Cardiac Markers Market, by Condition, 2016 – 2026 (US$ Mn)
TABLE 16 Europe Cardiac Markers Market, by Testing Type, 2016 – 2026 (US$ Mn)
TABLE 17 Europe Cardiac Markers Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 18 Asia Pacific Cardiac Markers Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 19 Asia Pacific Cardiac Markers Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 20 Asia Pacific Cardiac Markers Market, by Condition, 2016 – 2026 (US$ Mn)
TABLE 21 Asia Pacific Cardiac Markers Market, by Testing Type, 2016 – 2026 (US$ Mn)
TABLE 22 Asia Pacific Cardiac Markers Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 23 Latin America Cardiac Markers Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 24 Latin America Cardiac Markers Market, by Product, 2016 – 2026 (US$ Mn
TABLE 25 Latin America Cardiac Markers Market, by Condition, 2016 – 2026 (US$ Mn)
TABLE 26 Latin America Cardiac Markers Market, by Testing Type, 2016 – 2026 (US$ Mn)
TABLE 27 Latin America Cardiac Markers Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 28 Middle East and Africa Cardiac Markers Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 29 Middle East and Africa Cardiac Markers Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 30 Middle East and Africa Cardiac Markers Market, by Condition, 2016 – 2026 (US$ Mn)
TABLE 31 Middle East and Africa Cardiac Markers Market, by Testing Type, 2016 – 2026 (US$ Mn)
TABLE 32 Middle East and Africa Cardiac Markers Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 33 GE Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 34 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 35 Roche Diagnostics Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 36 Danaher Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 37 Bio-Rad Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 38 Becton, Dickinson and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 39 LSI Medience Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 40 Beckman Coulter, Inc. (Danaher Corporation): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 41 bioMerieux SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 42 Ortho Clinical Diagnostics: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 43 Siemens Healthcare Diagnostics: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 44 Randox Laboratories Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 45 Tosoh Bioscience: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 46 Quest Diagnostics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients